Matthias Cheung, PhD, Discusses Current Federal Legislation and Ongoing Policies Regarding Orphan Drugs and Rare Disease
Matthias Cheung, PhD, FCSHP, FASHP, a principal at Advanced Rx Consulting, LLC, and an adjunct professor of pharmacy practice at the University of the Pacific, Thomas J. Long School of Pharmacy and Health Services, discusses the circumstances and factors that catalyzed the passage of current legislation and regulatory policies for orphan drugs, rare diseases, and ultra-rare diseases.
This video was taken at the Academy of Managed Care Pharmacy's 25th Annual Meeting & Expo in San Diego, CA, on April 5, 2013.
California advocates worry that having half its children in Medi-Cal will mean poor access to care. But the real issue may be the growing number of poor children nationwide and the overall effect on Medicaid.
Reports say NIH would receive funds to collect DNA from 1 million volunteers, the National Cancer Institute would get research funds, and FDA would get support to regulate molecular diagnostic tests. The plans need funding from Congress.
The Genetic Information Nondiscrimination Act (GINA) protects most consumers from losing health coverage or their job if they pursue genetic testing. But authors of a new article in The New England Journal of Medicine explore the implications of testing for life, disability and long-term care insurance.